NCT05934474

Brief Summary

Most psychiatric research is based on the nosographic classifications used in current practice. At present, there is no diagnostic or prognostic biomarker for psychiatric pathologies commonly used in clinical practice. The study hypothesis is that peripheral inflammatory biomarkers could be common to several psychiatric disorders, in particular psychotic disorders (bipolar disorder, schizophreniform disorder, schizophrenia, depressive episode with psychotic features). The aim of this project is to set up a bio-collection of biological samples (peripheral blood samples) with associated phenotypic data (assessment of various symptoms using standardized scales in patients whose blood is sampled). The setting up of this cohort follows on from work carried out on a PsyCourse cohort also using a transdiagnostic approach in psychiatry, in order to be able to collaborate within a European research project.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
21mo left

Started Mar 2024

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress55%
Mar 2024Feb 2028

First Submitted

Initial submission to the registry

June 28, 2023

Completed
9 days until next milestone

First Posted

Study publicly available on registry

July 7, 2023

Completed
9 months until next milestone

Study Start

First participant enrolled

March 19, 2024

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 2, 2026

Expected
1.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

February 2, 2028

Last Updated

April 8, 2024

Status Verified

April 1, 2024

Enrollment Period

2.4 years

First QC Date

June 28, 2023

Last Update Submit

April 5, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Demonstration of the presence of diagnostic biomarkers and biomarkers of severity common to several psychiatric disorders.

    Biological analysis of IBIS-PSY biocollection samples

    2 hours

Secondary Outcomes (3)

  • Validation of a patient clustering method separating patients with severe symptoms from those with mild symptoms

    2 hours

  • Replication of a pan-transcriptomic study (A Transcriptome-Wide Association Study (TWAS))

    2 hours

  • Comparison of biomarkers between different psychiatric illnesses in order to develop models based on biological data that can help the physician adjust the diagnosis

    2 hours

Study Arms (1)

IBIS-PSY patients

Biological: Peripheral venipuncture blood sampling, as part of standard care proceduresOther: Interview with a psychiatrist

Interventions

Collection of 36 mL of blood

IBIS-PSY patients

Research project data collection

IBIS-PSY patients

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Participants will be recruited through the doctors who care for them on a regular medical basis, during a consultation or hospitalization in a psychiatric unit. After inclusion, an additional blood sample (4 tubes with a peripheral venous sample) will be taken by nurses from the psychiatric wards caring for the patient, during a blood sample taken as part of the patient's care. The sample will be transported to the Biological Resource Center (CRB) at Nantes University Hospital, where it will be stored along with all other study samples.

You may qualify if:

  • Major patient
  • Patient with one of the following diagnoses confirmed by a psychiatrist:
  • Characterized depressive episode with psychotic features,
  • Bipolar disorder type I
  • Bipolar disorder type II
  • Schizoaffective disorder
  • Schizophrenia
  • Schizophreniform disorder
  • Patient under psychiatric care at Nantes University Hospital
  • Patients weighing at least 45kg
  • Patient affiliated to a social security scheme or beneficiary of such a scheme
  • Patient who has given informed consent to participate in the study

You may not qualify if:

  • Pregnant,
  • History of cancer in the last 5 years,
  • Vaccination within the last 4 weeks,
  • Acute or chronic infection,
  • Medical history of organ transplant,
  • Medical history of autoimmune disease,
  • Hearing impairment making it impossible to complete study questionnaires,
  • Patient under court protection

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Nantes University Hospital

Nantes, 44100, France

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Peripheral blood sampling

MeSH Terms

Conditions

Psychotic DisordersBipolar Disorder

Interventions

Interviews as Topic

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic DisordersMental DisordersBipolar and Related DisordersMood Disorders

Intervention Hierarchy (Ancestors)

Data CollectionEpidemiologic MethodsInvestigative TechniquesHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public Health

Study Officials

  • Anne Sauvaget

    Nantes University Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 28, 2023

First Posted

July 7, 2023

Study Start

March 19, 2024

Primary Completion (Estimated)

August 2, 2026

Study Completion (Estimated)

February 2, 2028

Last Updated

April 8, 2024

Record last verified: 2024-04

Data Sharing

IPD Sharing
Will not share

Locations